Navalign LLC’s Gilead Sciences GILD Stock Holding History

Navalign LLC’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,114	Closed	-$137K	–	260
2025 Q4	$137K	Buy	+1,114	New	+$135K	0.03%	141

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Navalign LLC's GILD Position: Q1 2026 in Review

Navalign LLC sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 1,114 shares — an estimated $137K sold.

Navalign LLC first reported a position in GILD in Q4 2025 and held it in 1 quarter. The position peaked at $137K in Q4 2025. 2,315 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Navalign LLC reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
Navalign LLC sold 1,114 Gilead Sciences shares in Q1 2026, an estimated $137K.
Navalign LLC first reported a position in Gilead Sciences in Q4 2025 and held it in 1 quarter.
Navalign LLC's Gilead Sciences position peaked at $137K in Q4 2025.
2,315 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.